Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dianthus Therapeutics Inc (DNTH)

Dianthus Therapeutics Inc (DNTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,793,503
  • Shares Outstanding, K 42,876
  • Annual Sales, $ 6,240 K
  • Annual Income, $ -84,970 K
  • EBIT $ -140 M
  • EBITDA $ -146 M
  • 60-Month Beta 1.56
  • Price/Sales 296.73
  • Price/Cash Flow N/A
  • Price/Book 3.38

Options Overview Details

View History
  • Implied Volatility 72.06% (-6.82%)
  • Historical Volatility 57.54%
  • IV Percentile 23%
  • IV Rank 9.85%
  • IV High 229.28% on 08/25/25
  • IV Low 54.88% on 12/18/25
  • Expected Move (DTE 18) 4.00 (9.55%)
  • Put/Call Vol Ratio 3.67
  • Today's Volume 70
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 1.68
  • Today's Open Interest 1,188
  • Open Int (30-Day) 1,320
  • Expected Range 37.84 to 45.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.97
  • Number of Estimates 8
  • High Estimate -0.73
  • Low Estimate -1.69
  • Prior Year -0.81
  • Growth Rate Est. (year over year) -19.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.16 +4.16%
on 12/16/25
45.46 -7.97%
on 12/04/25
-2.20 (-5.00%)
since 11/26/25
3-Month
32.22 +29.83%
on 10/23/25
45.46 -7.97%
on 12/04/25
+5.12 (+13.95%)
since 09/26/25
52-Week
13.36 +212.98%
on 04/09/25
45.46 -7.97%
on 12/04/25
+18.83 (+81.87%)
since 12/26/24

Most Recent Stories

More News
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell...

DNTH : 41.83 (-3.06%)
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 41.83 (-3.06%)
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy...

DNTH : 41.83 (-3.06%)
Dianthus Therapeutics to Participate in Four Investor Conferences During November

NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 41.83 (-3.06%)
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase...

DNTH : 41.83 (-3.06%)
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function ...

DNTH : 41.83 (-3.06%)
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

NEW YORK and WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...

DNTH : 41.83 (-3.06%)
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...

DNTH : 41.83 (-3.06%)
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...

DNTH : 41.83 (-3.06%)
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...

DNTH : 41.83 (-3.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 44.93
2nd Resistance Point 44.16
1st Resistance Point 43.00
Last Price 41.83
1st Support Level 41.06
2nd Support Level 40.29
3rd Support Level 39.13

See More

52-Week High 45.46
Last Price 41.83
Fibonacci 61.8% 33.20
Fibonacci 50% 29.41
Fibonacci 38.2% 25.62
52-Week Low 13.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar